Law360, New York (December 11, 2013, 4:28 PM EST) -- The Nov. 23, 2013, announcement that the P5+1 countries — the United States, Russia, China, England and France plus Germany — and Iran reached "a set of initial understandings" on limiting and rolling back Iran's nuclear program did not have immediately obvious implications for U.S. manufacturers of medicine and medical devices. Indeed, the White House's fact sheet on the deal asserted that transactions related to Iran's purchase of food, agricultural commodities, medicine and medical devices "have been explicitly exempted from sanctions by Congress." That may be so, but any U.S. medicine or medical device manufacturer that has sought to send its product to Iran knows that, until very recently, in most cases the export had to be licensed under a time-consuming process....